Joseph J Park

List of Publications by Year
in descending order

21 papers	223 citations	1307366 7 h-index	1058333 14 g-index
21 all docs	21 docs citations	21 times ranked	441 citing authors

#	Article	IF	Citations
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	2.0	15
2	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	1.3	3
3	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	0.8	0
4	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	0.8	0
5	Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2022, 40, 505-505.	0.8	1
6	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	0.9	4
7	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e440-e452.	0.9	10
8	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	5.8	10
9	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	0.8	0
10	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. Journal of Clinical Oncology, 2021, 39, 406-406.	0.8	0
11	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	1.3	18
12	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2021, 39, 444-444.	0.8	0
13	Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.. Journal of Clinical Oncology, 2021, 39, 328-328.	0.8	4
14	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. Journal of Clinical Oncology, 2021, 39, e16526-e16526.	0.8	0
15	Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.. Journal of Clinical Oncology, 2021, 39, 4568-4568.	0.8	0
16	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39
17	Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience. Cancer Treatment and Research Communications, 2020, 25, 100251.	0.7	5
18	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta OncolÃ³gica, 2017, 56, 1746-1753.	0.8	38

#	Article	IF	Citations
19	Expression and alternative splicing of classical and nonclassical MHCI genes in the hippocampus and neuromuscular junction. Molecular and Cellular Neurosciences, 2016, 72, 34-45.	1.0	11
20	MHC Class I Limits Hippocampal Synapse Density by Inhibiting Neuronal Insulin Receptor Signaling. Journal of Neuroscience, 2014, 34, 11844-11856.	1.7	49
21	Interleukin-6 expands homeostatic space for peripheral T cells. Cytokine, 2013, 64, 532-540.	1.4	16